Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.

Avilar Therapeutics develops ASGPR Targeting Chimeras (ATACs) to degrade extracellular and membrane-bound proteins, addressing the challenge of targeting nearly 40% of human proteins implicated in various diseases. Their proprietary drug discovery platform enables the design of novel degraders aimed at establishing new treatment standards for serious medical conditions.

GC Therapeutics utilizes a "plug-and-play" induced pluripotent stem cell (iPSC) programming platform, TFome™, to efficiently generate various cell types for cell therapies. This technology addresses the challenges of scalability and accessibility in cell therapy development, enabling the rapid production of off-the-shelf iPSC-based medicines for gastrointestinal, neurological, and immunological diseases.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Ladder Bio’s Spiroligomer™ platform generates synthetic, DNA‑encoded libraries of rigid fused‑ring molecules that can be computationally designed and screened to produce nanomolar‑affinity protein binders with protease resistance, cell permeability, and low immunogenicity. The company supplies these drug‑like binders and compatible reagents to pharmaceutical, biotech, and diagnostic developers, offering fully synthetic GMP manufacturing that reduces cost and batch variability.

Nobias Therapeutics develops small molecule therapeutics targeting genetically-defined rare diseases, utilizing extensive genomic and health datasets in collaboration with pediatric academic medical centers. The company focuses on accelerating drug discovery for pediatric indications, with plans to expand into adult and non-rare disease markets.

Pleno has developed the RAPTOR Hypercoding platform, which enables rapid genomic testing from a single patient sample, delivering results within the same day. This technology addresses the high costs and lengthy workflows associated with traditional genomic testing methods, making advanced diagnostics more accessible and economically viable for clinical labs.

ProJenX develops Prosetin, a brain-penetrant MAP4K inhibitor therapy currently in clinical trials for Amyotrophic Lateral Sclerosis (ALS). This compound targets endoplasmic reticulum (ER) stress, a common feature across ALS subtypes, to rescue motor neuron loss. The company is also exploring MAP4K inhibition for other neurodegenerative disorders involving ER stress-mediated degeneration.

SonoThera is developing an ultrasound-mediated nonviral gene therapy platform that utilizes microbubbles for targeted delivery of genetic medicines to various human organs. This technology addresses the challenges of safety, efficacy, and biodistribution in gene therapy, enabling the delivery of large nucleic acid payloads without invasive procedures.

Trotana Therapeutics is focused on discovering and developing therapeutics that target RNA binding proteins to address unmet medical needs across various indications. By leveraging expertise in this novel field, the company aims to create effective treatments for conditions that currently lack viable options.

Truvian Sciences is developing an automated benchtop blood testing analyzer that delivers lab-accurate results for a suite of routine tests from a single drop of blood, eliminating the need for off-site lab processing. This technology provides healthcare providers with immediate insights during patient appointments, enhancing decision-making and patient care.